David Ipe

AbbVie (United States) — United States

Medicine · Health Sciences

12h-index1.6kcitations22works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(12), Lymphoma Diagnosis and Treatment(7), Hepatitis C virus research(6), CAR-T cell therapy research(4), Hepatitis B Virus Studies(3)

Publications22 total

POSTER: ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
Clinical Lymphoma Myeloma & Leukemia·2023
ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2
Hematological Oncology·2023· 5 citedOpen Access
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
Journal of Clinical Oncology·2023· 15 cited
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Journal of Clinical Oncology·2020· 102 citedOpen Access
CLL-185: Clinical Characteristics and Treatment Choices in Previously Untreated Elderly Patients (≥65 Years) With Chronic Lymphocytic Leukemia (CLL): Interim Analysis of the informCLL Real-World Registry
Clinical Lymphoma Myeloma & Leukemia·2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
Clinical Lymphoma Myeloma & Leukemia·2019· 33 citedOpen Access
PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL‐WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
HemaSphere·2019· 1 citedOpen Access
Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib
Blood·2018· 7 cited
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLLTM Real-World Registry
Blood·2018
Prognostic Testing and Treatment Approaches in Patients with Chronic Lymphocytic Leukemia: Clinical Experience from an Interim Analysis of the informCLLTM Real-World Registry
Blood·2018· 3 cited
Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients
Hepatology·2013· 43 citedOpen Access
1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY
Journal of Hepatology·2012· 13 citedOpen Access
Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C
Gastroenterology·2012· 91 citedOpen Access
Computerized Extraction of Electrocardiograms From Continuous 12‐Lead Holter Recordings Reduces Measurement Variability in a Thorough QT Study
The Journal of Clinical Pharmacology·2011· 14 cited
1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL
Journal of Hepatology·2011· 45 cited
1323 THE EFFECT OF HOST IL28B GENOTYPE ON EARLY VIRAL KINETICS DURING INTERFERON-FREE TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)
Journal of Hepatology·2011· 12 cited
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
The Lancet·2010· 335 cited
731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients
Journal of Hepatology·2006· 46 cited
Oral oseltamivir treatment of influenza in children
The Pediatric Infectious Disease Journal·2001· 711 cited
page 1 of 2Next →

Frequent Co-authors

Jacqueline C. Barrientos(5), Nilanjan Ghosh(5), Danielle M. Brander(5), Meghan Gutierrez(5), Reethi Iyengar(5), Jeff P. Sharman(5), Anthony R. Mato(4), Karen Kadish(4), Brian Tomlinson(4), Sandhya Upasani(4), Carlos I. Amaya-Chanaga(4), Nick Giafis(4), Laurie H. Sehn(4), Martine E.D. Chamuleau(4), Georg Lenz(4), Michael Roost Clausen(4), Corinne Haïoun(4), Koji Izutsu(4), Edith Szafer‐Glusman(4), Hung‐Yi Chiou(4)